Risks and costs of end-stage renal disease after heart transplantation

Transplantation

Volumn 66, Issue 12, 1998, Pages 1763-1770

  Hornberger, John ^a,b,c   Best, Jennie ^a   Geppert, Jeffrey ^d,e   McClellan, Mark ^b,d,e  

^a ROCHE BIOSCIENCE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Health Economics and Outcomes   (United States)

^d NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^e Acumen LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEART TRANSPLANTATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; COST-BENEFIT ANALYSIS; FEMALE; HEALTH EXPENDITURES; HEART TRANSPLANTATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MARKOV CHAINS; MIDDLE AGED;

EID: 0032573685     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00034     Document Type: Article

References (28)

1. Devineni R, McKenzie N, Keown P, Kostuk W, Stiller C, Silver M. Cyclosporine in cardiac transplantation. Can J Surg 1984; 3: 252.
2. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997; 63: 664.
3. Goral S, Ynares C, Shyr Y, Yeoh TK, Johnson HK. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. J Heart Lung Transplant 1997; 16: 1106.
4. Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 1987; 9: 12.
5. Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients - a seven year follow-up. Transplantation 1990; 50: 589.
6. Hakim M, Wallwork J, English T. Cyclosporin A in cardiac transplantation: medium term results in 62 patients. Ann Thorac Surg 1988; 46: 495.
7. Kuo PC, Luikart H, Busse-Henry S, et al. Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients. Clin Transplant 1995; 9: 92.
8. Lewis RM, Van Buren CT, Radovancevic B, et al. Impact of long term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 1991; 10(pt 1): 63.
9. McKenzie N, Keown P, Stiller C, Kostuk W, Campbell C, Keith F. Effects of cyclosporine on renal function following orthotopic heart transplantation. J Heart Transplant 1985; 4: 400.
10. Myers BD, Ross J, Newton RN, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
11. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
12. Myers BD, Newton L, Oyer P. The case against the indefinite use of cyclosporine. Transplant Proc 1991; 23: 41
13. Pham SM, Kormos RL, Kawai A, et al. Tacrolimus (FK506) in clinical cardiac transplantation: a five year experience. Transplant Proc 1996; 28: 1002.
14. Rinaldi M, Pellegrini C, Martinelli L, et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 1997; 16: 1001.
15. Spratt P, Esmore D, Baron D, Shanahan MX, Farnsworth AE, Chang VP. Effectiveness of minimal dosage cyclosporine in limiting toxicity and rejection. J Heart Lung Transplant 1986; 5: 8.
16. Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997; 11: 1.
17. Tsamandas AC, Pham SM, Seaberg EC, et al. Adult heart transplantation under tacrolimus (FK50) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant 1997; 16: 723.
18. Zietse R, Balk AH, Dorpel MA.v.d., Meeter K, Bos E, Weimar W. Time course of the decline in renal function in Cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14: 1.
19. Torrance GW, Siegel JE, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold ME, Russell LB, Siegel JE, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
20. Hosenpud JD, Bennet LE, Keck BM, Fiol B, Novick RJ. The registry of the international society for heart and lung transplantation: fourteenth official report - 1997. J Heart Lung Transplant 1997; 16: 691.
21. U.S. Renal Data System. USRDS 1997 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1997.
22. Current consumer price indices. Washington, DC: Bureau of Labor Statistics, 1996.
23. End stage renal disease research report 1993-1995. Baltimore, MD: Health Care Financing Administration, U.S. Dept. of Health and Human Services, 1997.
24. Medicare program. Medicare coverage of prescription drugs used in immunosuppressive therapy (42 CFR part 410). Federal Register. February 16, 1995: 60.
25. Eggers P. Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 1992; 12: 284.
26. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold ME, Russell LB, Siegel JE, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
27. http://www.unos.org/Newsroom/critdata_transplants_surviv2.htm. Accessed November 16, 1998.
28. Garrison LP. Assessing the cost-effectiveness of development and use of the total artificial heart. In: VanAntwerp M, Hognes JR, eds. The artificial heart: prototypes, policies, and patients. Washington, D.C.: National Academy Press, 1991.